Advertisement

Topics

Adimab Publishes Biophysical Performance Metrics That Predict Drug-Like Properties of Antibody-Based Therapeutics

09:00 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced the publication of a study focused on the biophysical characterization of 137 clinical-stage a...

Other Sources for this Article

Company Contact:
Adimab, LLC.
Guy Van Meter, 603-653-5775
Vice President, Business Development
or
Media Contact:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Adimab Publishes Biophysical Performance Metrics That Predict Drug-Like Properties of Antibody-Based Therapeutics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...